Vabysmo Use In Pregnancy & Lactation

Women of childbearing potential: Women of childbearing potential should use effective contraception during treatment and for at least 3 months following the last intravitreal injection of faricimab.
Pregnancy: There are no or limited amount of data from the use of faricimab in pregnant women. The systemic exposure to faricimab is low after ocular administration, but due to its mechanism of action (i.e. VEGF inhibition), faricimab must be regarded as potentially teratogenic and embryo-/foetotoxic (see Pharmacology: Toxicology: Preclinical safety data under Actions).
Faricimab should not be used during pregnancy unless the potential benefit outweighs the potential risk to the foetus.
Breast-feeding: It is unknown whether faricimab is excreted in human milk. A risk to the breast-fed newborn/infant cannot be excluded. Vabysmo should not be used during breast-feeding. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from faricimab therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Fertility: No effects on reproductive organs or fertility were observed in a 6-month cynomolgus monkey study with faricimab (see Pharmacology: Toxicology: Preclinical safety data under Actions).